Gastric Cancer
Conditions
Interventions
Observation group:None
Sponsors
Nanjing Drum Tower Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: (1) Patients must be between 18 and 80 years of age. (2) Patients must have gastric cancer confirmed by endoscopy and pathology, assessed as locally advanced, and receiving neoadjuvant therapy combined with immunotherapy. (3) Preoperative disease evaluation according to RECIST criteria must indicate stable disease (SD) or partial response (PR). (4) The interval between the last neoadjuvant treatment and surgery must be 3-4 weeks. (5) Patients must provide signed informed consent.
Exclusion criteria
Exclusion criteria: (1) Patients who did not complete the neoadjuvant treatment course due to treatment complications or tumor progression, or who underwent emergency surgery due to reasons such as gastrointestinal bleeding or pyloric obstruction. (2) Lack of clinical data or follow-up data. (3) Discovery of distant metastasis during surgery, with only palliative gastrectomy performed. (4) History of other malignancies. (5) History of confirmed autoimmune diseases. (6) Use of anticoagulant or immunosuppressive medications prior to surgery. (7) Patients who explicitly refuse to participate in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| In gastric cancer patients undergoing immune-combined neoadjuvant therapy, the study aims to investigate the correlation between pre-treatment serum albumin levels, history of hypertension, changes in tumor marker levels after treatment, and postoperative pathological Tumor Regression Grade (TRG).; | — |
Countries
China
Contacts
Public ContactXiaofei Shen
Nanjing Drum Tower Hospital
Outcome results
None listed